Assessment of CD52 Expression in Double-Hit and Double-Expressor Lymphomas: Implications for Clinical Trial Eligibility
Year: 2017
Type: article
Source: Blood
Institutions: Brigham and Women's Hospital, Dana-Farber Cancer Institute
Language: English
Subfield: Pathology and Forensic Medicine
Field: Medicine
Domain: Health Sciences
Open Access status: closed
OpenAlex ID: W3163537245
